Martin Maron to Death, Sudden, Cardiac
This is a "connection" page, showing publications Martin Maron has written about Death, Sudden, Cardiac.
Connection Strength
13.994
-
Maron MS, Rowin EJ, Maron BJ. Letter by Maron et al Regarding Article, "Sudden Cardiac Death in National Collegiate Athletic Association Athletes". Circulation. 2024 Sep 17; 150(12):e255-e256.
Score: 0.704
-
Maron BJ, Rowin EJ, Maron MS. Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: Twenty years with the implantable cardioverter-defibrillator. Heart Rhythm. 2021 06; 18(6):1012-1023.
Score: 0.547
-
Maron BJ, Rowin EJ, Maron MS. Hypertrophic Cardiomyopathy: Is a 'Cure' Coming . . . Or Is It Already Here? Am J Med. 2020 08; 133(8):886-888.
Score: 0.529
-
Maron MS, Brush J, Rowin EJ, Maron BJ. Back to the future: Predicting sudden death in hypertrophic cardiomyopathy relying on individual risk markers and physician judgment without mathematical scoring. Heart Rhythm. 2021 01; 18(1):148-150.
Score: 0.528
-
Maron BJ, Mackey-Bojack S, Facile E, Duncanson E, Rowin EJ, Maron MS. Hypertrophic Cardiomyopathy and Sudden Death Initially Identified at Autopsy. Am J Cardiol. 2020 07 15; 127:139-141.
Score: 0.519
-
Maron BJ, Rowin EJ, Maron MS. Concerns About the HCM Risk-Kids Study. JAMA Cardiol. 2020 03 01; 5(3):362-363.
Score: 0.514
-
Maron BJ, Harris KM, Maron MS. The Guidant Affair revisited?but this time with good news. Heart Rhythm. 2020 03; 17(3):512-513.
Score: 0.499
-
Maron BJ, Rowin EJ, Maron MS. Paradigm of Sudden Death Prevention in Hypertrophic Cardiomyopathy. Circ Res. 2019 08 02; 125(4):370-378.
Score: 0.493
-
Maron MS, Rowin EJ, Wessler BS, Mooney PJ, Fatima A, Patel P, Koethe BC, Romashko M, Link MS, Maron BJ. Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy. JAMA Cardiol. 2019 07 01; 4(7):644-657.
Score: 0.490
-
Maron BJ, Estes NAM, Maron MS. Is It Fair to Screen Only Competitive Athletes for Sudden Death Risk, or Is It Time to Level the Playing Field? Am J Cardiol. 2018 04 15; 121(8):1008-1010.
Score: 0.445
-
Maron BJ, Nishimura RA, Maron MS. Shared decision-making in HCM. Nat Rev Cardiol. 2017 03; 14(3):125-126.
Score: 0.414
-
Maron BJ, Maron MS. Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy. Heart Rhythm. 2016 05; 13(5):1155-1165.
Score: 0.385
-
Maron BJ, Rowin EJ, Casey SA, Garberich RF, Maron MS. What Do Patients With Hypertrophic Cardiomyopathy Die from? Am J Cardiol. 2016 Feb 01; 117(3):434-5.
Score: 0.382
-
Maron BJ, Casey SA, Chan RH, Garberich RF, Rowin EJ, Maron MS. Independent Assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy. Am J Cardiol. 2015 Sep 01; 116(5):757-64.
Score: 0.370
-
Maron MS. The role of cardiovascular magnetic resonance in sudden death risk stratification in hypertrophic cardiomyopathy. Card Electrophysiol Clin. 2015 Jun; 7(2):187-93.
Score: 0.369
-
Maron MS. Family History of Sudden Death Should Be a Primary Indication for Implantable Cardioverter Defibrillator in Hypertrophic Cardiomyopathy. Can J Cardiol. 2015 Nov; 31(11):1402-6.
Score: 0.368
-
Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, Lesser JR, Gruner C, Crean AM, Rakowski H, Udelson JE, Rowin E, Lombardi M, Cecchi F, Tomberli B, Spirito P, Formisano F, Biagini E, Rapezzi C, De Cecco CN, Autore C, Cook EF, Hong SN, Gibson CM, Manning WJ, Appelbaum E, Maron MS. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014 Aug 05; 130(6):484-95.
Score: 0.349
-
Maron BJ, Rowin EJ, Casey SA, Haas TS, Chan RH, Udelson JE, Garberich RF, Lesser JR, Appelbaum E, Manning WJ, Maron MS. Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age. Circulation. 2013 Feb 05; 127(5):585-93.
Score: 0.312
-
Maron BJ, Olivotto I, Maron MS. The dilemma of left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy: do patients with gradients really deserve prophylactic defibrillators? Eur Heart J. 2006 Aug; 27(16):1895-7.
Score: 0.199
-
Aimo A, Todiere G, Barison A, Tomasoni D, Panichella G, Masri A, Maron MS. Diagnosis and management of hypertrophic cardiomyopathy: European vs. American guidelines. Heart Fail Rev. 2025 Mar; 30(2):315-325.
Score: 0.178
-
Chan RH, van der Wal L, Liberato G, Rowin E, Soslow J, Maskatia S, Chan S, Shah A, Fogel M, Hernandez L, Anwar S, Voges I, Carlsson M, Buddhe S, Laser KT, Greil G, Valsangiacomo-Buechel E, Olivotto I, Wong D, Wolf C, Grotenhuis H, Rickers C, Hor K, Rutz T, Kutty S, Samyn M, Johnson T, Hasbani K, Moore JP, Sieverding L, Detterich J, Parra R, Chungsomprasong P, Toro-Salazar O, Roest AAW, Dittrich S, Brun H, Spinner J, Lai W, Dyer A, Jablonowsk R, Meierhofer C, Gabbert D, Prsa M, Patel JK, Hornung A, Diab SG, House AV, Rakowski H, Benson L, Maron MS, Grosse-Wortmann L. Myocardial Scarring and Sudden Cardiac Death in Young Patients With Hypertrophic Cardiomyopathy: A Multicenter Cohort Study. JAMA Cardiol. 2024 Nov 01; 9(11):1001-1008.
Score: 0.177
-
Siontis KC, Ommen SR, Maron MS, Maron BJ. Re-examining family history of sudden death as a risk marker in hypertrophic cardiomyopathy. Heart Rhythm. 2024 Oct; 21(10):1838-1842.
Score: 0.173
-
Bonaventura J, Rowin EJ, Chan RH, Chin MT, Puchnerova V, Polakova E, Macek M, Votypka P, Batorsky R, Perera G, Koethe B, Veselka J, Maron BJ, Maron MS. Relationship Between Genotype Status and Clinical Outcome in Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2024 May 21; 13(10):e033565.
Score: 0.172
-
Maron MS, Rowin EJ, Maron BJ. The Paradigm of Sudden Death Prevention in Hypertrophic Cardiomyopathy. Am J Cardiol. 2024 02 01; 212S:S64-S76.
Score: 0.168
-
Maron BJ, Rowin EJ, Maron MS. Advances in the Management of Hypertrophic Cardiomyopathy Leading to Low Disease-Related Mortality in 2023. Am J Cardiol. 2024 02 01; 212S:S77-S82.
Score: 0.168
-
Maron MS, Mitten M, Borchers J, Rowin EJ, Maron BJ. Medical and Legal Determinants of Sports Eligibility for Young Competitive Athletes With Cardiovascular Disease. J Am Coll Cardiol. 2023 08 29; 82(9):828-832.
Score: 0.163
-
Maron MS, Rowin EJ, Bonaventura J, Maron BJ. Do Implantable Cardioverter-Defibrillators Really Belong on the Athlete Field? Am J Cardiol. 2023 08 01; 200:236-238.
Score: 0.162
-
Maron MS, Rowin E, Spirito P, Maron BJ. Differing strategies for sudden death prevention in hypertrophic cardiomyopathy. Heart. 2023 03 27; 109(8):589-594.
Score: 0.159
-
Abdelfattah OM, Martinez M, Sayed A, ElRefaei M, Abushouk AI, Hassan A, Masri A, Winters SL, Kapadia SR, Maron BJ, Rowin E, Maron MS. Temporal and Global Trends of the Incidence of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. JACC Clin Electrophysiol. 2022 11; 8(11):1417-1427.
Score: 0.153
-
Maron BJ, Rowin EJ, Madias C, Dolan N, Maron MS. Cats Have Nine Lives but This Hypertrophic Cardiomyopathy Patient Has Had Ten (So Far). Am J Cardiol. 2022 04 01; 168:163-165.
Score: 0.147
-
Maron BJ, Rowin EJ, Maron MS. After 60 Years Hypertrophic Cardiomyopathy is Finally Recognized as a Contemporary Treatable Disease With Low Mortality and Morbidity, But is This Paradigm Under-Recognized in the Literature? Am J Cardiol. 2021 03 01; 142:136-137.
Score: 0.135
-
Shirani J, Aurshiya R, Elshaikh A, Olenchock SA, Rowin EJ, Maron MS, Maron BJ. Low Risk of Hypertrophic Cardiomyopathy With Contemporary Management Strategies Implemented in Non-Referral Regional Community-Based Practices. Am J Cardiol. 2021 03 01; 142:130-135.
Score: 0.135
-
Rowin EJ, Burrows A, Madias C, Estes NAM, Link MS, Maron MS, Maron BJ. Long-Term Outcome in High-Risk Patients With Hypertrophic Cardiomyopathy After Primary Prevention Defibrillator Implants. Circ Arrhythm Electrophysiol. 2020 10; 13(10):e008123.
Score: 0.133
-
Maron MS, Steiger N, Burrows A, Madias C, Weinstock J, Link MS, Rowin EJ, Maron BJ. Evidence That Subcutaneous Implantable Cardioverter-Defibrillators Are Effective and Reliable in Hypertrophic Cardiomyopathy. JACC Clin Electrophysiol. 2020 08; 6(8):1019-1021.
Score: 0.132
-
Rowin EJ, Sridharan A, Madias C, Firely C, Koethe B, Link MS, Maron MS, Maron BJ. Prediction and Prevention of Sudden Death in Young Patients (<20 years) With Hypertrophic Cardiomyopathy. Am J Cardiol. 2020 08 01; 128:75-83.
Score: 0.130
-
Maron MS, Rowin EJ, Maron BJ. Editorial commentary: Hold your horses (and mice, rats, and cats): How relevant really are animal models of hypertrophic cardiomyopathy? Trends Cardiovasc Med. 2021 01; 31(1):32-33.
Score: 0.127
-
Maron BJ, Thompson PD, Maron MS. There is No Reason to Adopt ECG s and Abandon American Heart Association/American College of Cardiology History and Physical Screening for Detection of Cardiovascular Disease in the Young. J Am Heart Assoc. 2019 07 16; 8(14):e013007.
Score: 0.123
-
Thiene G, Rizzo S, Schiavon M, Maron MS, Zorzi A, Corrado D, Maron BJ, Basso C. Structurally Normal Hearts Are Uncommonly Associated With Sudden Deaths in Athletes and Young People. J Am Coll Cardiol. 2019 06 18; 73(23):3031-3032.
Score: 0.122
-
Maron BJ, Rowin EJ, Maron MS. Global Burden of Hypertrophic?Cardiomyopathy. JACC Heart Fail. 2018 05; 6(5):376-378.
Score: 0.113
-
Maron BJ, Casey SA, Olivotto I, Sherrid MV, Semsarian C, Autore C, Ahmed A, Boriani G, Francia P, Winters SL, Giudici M, Koulova A, Garberich R, Rowin EJ, Sears SF, Maron MS, Spirito P. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators. Circ Arrhythm Electrophysiol. 2018 04; 11(4):e005820.
Score: 0.112
-
Rowin EJ, Maron BJ, Abt P, Kiernan MS, Vest A, Costantino F, Maron MS, DeNofrio D. Impact of Advanced Therapies for Improving Survival to Heart Transplant in Patients with Hypertrophic Cardiomyopathy. Am J Cardiol. 2018 04 15; 121(8):986-996.
Score: 0.111
-
Rowin EJ, Maron MS, Chan RH, Hausvater A, Wang W, Rastegar H, Maron BJ. Interaction of Adverse Disease Related Pathways in Hypertrophic Cardiomyopathy. Am J Cardiol. 2017 Dec 15; 120(12):2256-2264.
Score: 0.108
-
Maron MS. J Point Elevation in Hypertrophic?Cardiomyopathy: Riding a New Wave in Risk Stratification? JACC Clin Electrophysiol. 2017 10; 3(10):1143-1145.
Score: 0.108
-
Maron MS. Risk Stratification in Hypertrophic Cardiomyopathy: Highly Effective, But Could It Be Better? Circ Cardiovasc Imaging. 2017 07; 10(7).
Score: 0.107
-
Maron MS, Rowin EJ, Maron BJ. How to Image Hypertrophic Cardiomyopathy. Circ Cardiovasc Imaging. 2017 07; 10(7).
Score: 0.107
-
Wang W, Lian Z, Rowin EJ, Maron BJ, Maron MS, Link MS. Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy. Circ Arrhythm Electrophysiol. 2017 Mar; 10(3).
Score: 0.104
-
Weinstock J, Bader YH, Maron MS, Rowin EJ, Link MS. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience. J Am Heart Assoc. 2016 Feb 12; 5(2).
Score: 0.097
-
Semsarian C, Ingles J, Maron MS, Maron BJ. Reply: What Is the True Prevalence of Hypertrophic Cardiomyopathy? J Am Coll Cardiol. 2015 Oct 20; 66(16):1846-1847.
Score: 0.095
-
Maron BJ, Rowin EJ, Casey SA, Link MS, Lesser JR, Chan RH, Garberich RF, Udelson JE, Maron MS. Hypertrophic Cardiomyopathy in?Adulthood Associated With Low?Cardiovascular Mortality With Contemporary Management Strategies. J Am Coll Cardiol. 2015 May 12; 65(18):1915-28.
Score: 0.092
-
Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015 Mar 31; 65(12):1249-1254.
Score: 0.091
-
Maron BJ, Weiner HL, Maron MS, Roberts WC. Surviving malignant hypertrophic cardiomyopathy with all major complications in a single patient. Am J Cardiol. 2015 Feb 01; 115(3):402-4.
Score: 0.089
-
Maron MS. My approach to clinical management of hypertrophic cardiomyopathy. Trends Cardiovasc Med. 2014 Oct; 24(7):314-5.
Score: 0.087
-
Kim J, Parikh P, Mahboob M, Arrighi JA, Atalay MK, Rowin EJ, Maron MS. Asymptomatic young man with Danon disease. Tex Heart Inst J. 2014 Jun; 41(3):332-4.
Score: 0.086
-
Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA, Shannon KM, Ashley EA, Day SM, Pacileo G, Formisano F, Devoto E, Anastasakis A, Bos JM, Woo A, Autore C, Pass RH, Boriani G, Garberich RF, Almquist AK, Russell MW, Boni L, Berger S, Maron MS, Link MS. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013 Apr 09; 61(14):1527-35.
Score: 0.080
-
Alsheikh-Ali AA, Link MS, Semsarian C, Shen WK, Estes NA, Maron MS, Haas TS, Formisano F, Boriani G, Spirito P, Maron BJ. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients. Heart Rhythm. 2013 Feb; 10(2):214-8.
Score: 0.077
-
Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet. 2013 Jan 19; 381(9862):242-55.
Score: 0.076
-
Rowin EJ, Maron BJ, Appelbaum E, Link MS, Gibson CM, Lesser JR, Haas TS, Udelson JE, Manning WJ, Maron MS. Significance of false negative electrocardiograms in preparticipation screening of athletes for hypertrophic cardiomyopathy. Am J Cardiol. 2012 Oct 01; 110(7):1027-32.
Score: 0.076
-
Maron MS. Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2012 Feb 01; 14:13.
Score: 0.073
-
Maron BJ, Maron MS, Semsarian C. Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors. Heart Rhythm. 2012 Jan; 9(1):57-63.
Score: 0.071
-
Heffernan KS, Maron MS, Patvardhan EA, Karas RH, Kuvin JT. Relation of pulse pressure to blood pressure response to exercise in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2011 Feb 15; 107(4):600-3.
Score: 0.068
-
Giada F, Biffi A, Cannom DS, Cappato R, Capucci A, Corrado D, Delise P, Drezner JA, El-Sherif N, Estes M, Furlanello F, Heidbuchel H, Inama G, Lindsay BD, Maron BJ, Maron MS, Mont L, Olshansky B, Pelliccia A, Thiene G, Viskin S, Zeppilli P, Natale A, Raviele A. Sports and arrhythmias: a report of the International Workshop Venice Arrhythmias 2009. Eur J Cardiovasc Prev Rehabil. 2010 Oct; 17(5):607-12.
Score: 0.067
-
Spirito P, Autore C, Rapezzi C, Bernab? P, Badagliacca R, Maron MS, Bongioanni S, Coccolo F, Estes NA, Barill? CS, Biagini E, Quarta G, Conte MR, Bruzzi P, Maron BJ. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation. 2009 Apr 07; 119(13):1703-10.
Score: 0.060
-
Carrick RT, Ahamed H, Sung E, Maron MS, Madias C, Avula V, Studley R, Bao C, Bokhari N, Quintana E, Rajesh-Kannan R, Maron BJ, Wu KC, Rowin EJ. Identification of high-risk imaging features in hypertrophic cardiomyopathy using electrocardiography: A deep-learning approach. Heart Rhythm. 2024 08; 21(8):1390-1397.
Score: 0.042
-
Maron BJ, Estes NAM, Rowin EJ, Maron MS, Reynolds MR. Development of the Implantable Cardioverter-Defibrillator: JACC Historical Breakthroughs in Perspective. J Am Coll Cardiol. 2023 07 25; 82(4):353-373.
Score: 0.041
-
Maron BJ, Estes NA, Maron MS, Almquist AK, Link MS, Udelson JE. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation. 2003 Jun 17; 107(23):2872-5.
Score: 0.040
-
Wang RS, Rowin EJ, Maron BJ, Maron MS, Maron BA. A novel patient-patient network medicine approach to refine hypertrophic cardiomyopathy subgrouping: implications for risk stratification. Cardiovasc Res. 2023 05 02; 119(3):e125-e127.
Score: 0.040
-
Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, Cecchi F, Maron BJ. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003 Jan 23; 348(4):295-303.
Score: 0.039
-
Bonaventura J, Rowin EJ, Maron MS, Maron BJ. Risks of the Athletic Field Revisited: Report of Unusual Occurrences of Cardiac Arrest and Sudden Death in Professional Soccer Players. Am J Med. 2023 03; 136(3):315-321.
Score: 0.039
-
Brignole M, Cecchi F, Anastasakis A, Crotti L, Deharo JC, Elliott PM, Fedorowski A, Kaski JP, Limongelli G, Maron MS, Olivotto I, Ommen SR, Parati G, Shen W, Ungar A, Wilde A. Syncope in hypertrophic cardiomyopathy (part II): An expert consensus statement on the diagnosis and management. Int J Cardiol. 2023 01 01; 370:330-337.
Score: 0.039
-
Butzner M, Sarocco P, Maron MS, Rowin E, Teng CC, Stanek E, Tan H, Robertson LA. Characteristics of Patients With Obstructive Hypertrophic Cardiomyopathy in Real-World Community-Based Cardiovascular Practices. Am J Cardiol. 2022 07 01; 174:120-125.
Score: 0.037
-
Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Dearani JA, Rowin EJ, Maron MS, Sherrid MV. Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022 02 01; 79(4):390-414.
Score: 0.037
-
Rowin EJ, Maron MS, Adler A, Albano AJ, Varnava AM, Spears D, Marsy D, Heitner SB, Cohen E, Leong KMW, Winters SL, Martinez MW, Koethe BC, Rakowski H, Maron BJ. Importance of newer cardiac magnetic resonance-based risk markers for sudden death prevention in hypertrophic cardiomyopathy: An international multicenter study. Heart Rhythm. 2022 05; 19(5):782-789.
Score: 0.036
-
Sridharan A, Maron MS, Carrick RT, Madias CA, Huang D, Cooper C, Drummond J, Maron BJ, Rowin EJ. Impact of comorbidities on atrial fibrillation and sudden cardiac death in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2022 01; 33(1):20-29.
Score: 0.036
-
Papanastasiou CA, Zegkos T, Karamitsos TD, Rowin EJ, Maron MS, Parcharidou D, Kokkinidis DG, Karvounis H, Rimoldi O, Maron BJ, Efthimiadis GK. Prognostic role of left ventricular apical aneurysm in hypertrophic cardiomyopathy: A systematic review and meta-analysis. Int J Cardiol. 2021 06 01; 332:127-132.
Score: 0.035
-
Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P, Kimmelstiel C, Kittleson M, Link MS, Maron MS, Martinez MW, Miyake CY, Schaff HV, Semsarian C, Sorajja P. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020 12 22; 76(25):3022-3055.
Score: 0.034
-
Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P, Kimmelstiel C, Kittleson M, Link MS, Maron MS, Martinez MW, Miyake CY, Schaff HV, Semsarian C, Sorajja P. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020 12 22; 76(25):e159-e240.
Score: 0.034
-
Maron BJ, Levine BD, Washington RL, Baggish AL, Kovacs RJ, Maron MS. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 2: Preparticipation Screening for Cardiovascular Disease in Competitive Athletes: A Scientific Statement From the American Heart Association and American College of Cardiology. Circulation. 2015 Dec 01; 132(22):e267-72.
Score: 0.024
-
Maron BJ, Thompson PD, Ackerman MJ, Balady G, Berger S, Cohen D, Dimeff R, Douglas PS, Glover DW, Hutter AM, Krauss MD, Maron MS, Mitten MJ, Roberts WO, Puffer JC. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2007 Mar 27; 115(12):1643-455.
Score: 0.013